Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Bluebird bio went public in 2013, raising approximately $116m through its IPO. The company has developed three US Food and ...

UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to the oncolytic virus ICVB-1042 ...

Incyte and Genesis have entered a strategic partnership for the research, discovery and development of new small-molecule ...

The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are ...

CSL Behring KK has gained approval from Japan's MHLW to manufacture and market subcutaneous injection 200mg Andembry pens.

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood ...

How can pharmaceutical firms shore up their sustainability credentials at a time when the entire research landscape is turning on its head? A recent webinar from supply chain leaders World Courier and ...

BMS' Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

ImmunityBio has gained the FDA authorisation for an EAP to supply an alternative source of BCG for treating bladder cancer.